基于临床表现和病理学特征的阿尔茨海默病临床亚型研究进展

周娟, 曾德阳, 刘小畅, 曾燕, 黄招兰, 杨学, 汪星, 谭伟

PDF(549 KB)
PDF(549 KB)
重庆医科大学学报 ›› 2025, Vol. 50 ›› Issue (04) : 476-481. DOI: 10.13406/j.cnki.cyxb.003773
综述

基于临床表现和病理学特征的阿尔茨海默病临床亚型研究进展

作者信息 +

Research advances in clinical subtypes of Alzheimer’s disease based on clinical manifestations and pathological features

Author information +
History +

摘要

阿尔茨海默病(Alzheimer’s disease,AD)是一种病理和临床表型异质性很强的神经退行性疾病,是最常见的痴呆病因,AD异质性给诊断、治疗及新药疗效评估带来了挑战。该综述基于临床表现、遗传学特征和病理学特征概述了AD主要临床亚型的最新进展,早发和迟发型AD临床亚型可能具有相同的症状,但其病因、发病年龄、表现方式、疾病进展以及相关疾病方面有所不同。典型AD和非典型AD在临床表现、病理特征和诊断标准上存在明显差异。基于影像和组学数据的AD亚型研究也取得了诸多研究进展,该综述也简要概括了AD分子病理异质性,深入理解这些异质性对于诊断、制定药物治疗策略和临床管理至关重要。

Abstract

Alzheimer’s disease(AD) is a neurodegenerative disease with highly heterogeneous pathological and clinical manifestations,and it is the most common cause of dementia. This heterogeneity poses challenges for diagnosis,treatment,and evaluating novel pharmacological efficacy. This review summarizes the latest progress in the major clinical subtypes of AD based on clinical manifestations,genetic,and pathological features. Early-onset and late-onset AD clinical subtypes may share the same symptoms but differ in etiology,age of onset,mode of presentation,disease progression,and associated comorbidities. Typical and atypical AD differ significantly in clinical manifestations,pathological features,and diagnostic criteria. Research on AD subtypes based on imaging and omics data has also made considerable progress. This review also outlines the molecular pathological heterogeneity of AD. A deep understanding of these heterogeneities is crucial for diagnosis,the formulation of pharmacological treatment strategies,and clinical management.

关键词

阿尔茨海默病 / 异质性 / 临床亚型 / 分子病理 / 分子影像

Key words

Alzheimer’s disease / heterogeneity / clinical subtype / molecular pathology / molecular imaging

中图分类号

R741

引用本文

导出引用
周娟 , 曾德阳 , 刘小畅 , . 基于临床表现和病理学特征的阿尔茨海默病临床亚型研究进展. 重庆医科大学学报. 2025, 50(04): 476-481 https://doi.org/10.13406/j.cnki.cyxb.003773
Zhou Juan, Zeng Deyang, Liu Xiaochang, et al. Research advances in clinical subtypes of Alzheimer’s disease based on clinical manifestations and pathological features[J]. Journal of Chongqing Medical University. 2025, 50(04): 476-481 https://doi.org/10.13406/j.cnki.cyxb.003773

参考文献

1
Khan S Barve KH Kumar MS. Recent advancements in pathogenesis,diagnostics and treatment of Alzheimer’s disease[J]. Curr Neuropharmacol202018(11):1106-1125.
2
Badhwar A Peggy McFall G Sapkota S,et al. A multiomics approach to heterogeneity in Alzheimer’s disease:focused review and roadmap[J]. Brain2020143(5):1315-1331.
3
Koychev I Hofer M Friedman N. Correlation of Alzheimer disease neuropathologic staging with amyloid and tau scintigraphic imaging biomarkers[J]. J Nucl Med202061(10):1413-1418.
4
Mendez MF. Early-onset Alzheimer’s disease:nonamnestic subtypes and type 2 AD[J]. Arch Med Res201243(8):677-685.
5
Mantyh WG Cochran JN Taylor JW,et al. Early-onset Alzheimer’s disease explained by polygenic risk of late-onset disease?[J]. Alzheimers Dement (Amst)202315(4):e12482.
6
Andrade-Guerrero J Santiago-Balmaseda A Jeronimo-Aguilar P,et al. Alzheimer’s disease:an updated overview of its genetics[J]. Int J Mol Sci202324(4):3754.
7
Reitz C Rogaeva E Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease:a distinction without a difference?[J].Neurol Genet20206(5):e512.
8
Bateman RJ Aisen PS De Strooper B,et al. Autosomal-dominant Alzheimer’s disease:a review and proposal for the prevention of Alzheimer’s disease[J]. Alzheimers Res Ther20113(1):1.
9
Arber C Belder CRS Tomczuk F,et al. The presenilin 1 mutation P436S causes familial Alzheimer’s disease with elevated Aβ43 and atypical clinical manifestations[J]. Alzheimers Dement202420(7):4717-4726.
10
Tellechea P Pujol N Esteve-Belloch P,et al. Early- and late-onset Alzheimer disease:are they the same entity?[J]. Neurologia (Engl Ed)201833(4):244-253.
11
Livingston G Huntley J Sommerlad A,et al. Dementia prevention,intervention,and care:2020 report of the lancet commission[J]. Lancet2020396(10248):413-446.
12
Deckers K van Boxtel MPJ Schiepers OJG,et al. Target risk factors for dementia prevention:a systematic review and Delphi consensus study on the evidence from observational studies[J]. Int J Geriatr Psychiatry201530(3):234-246.
13
Sirkis DW Bonham LW Johnson TP,et al. Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease[J]. Mol Psychiatry202227(6):2674-2688.
14
Spina S La Joie R Petersen C,et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease[J]. Brain2021144(7):2186-2198.
15
Möller C Vrenken H Jiskoot L,et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease[J]. Neurobiol Aging201334(8):2014-2022.
16
Boyle PA Yu L Wilson RS,et al. Person-specific contribution of neuropathologies to cognitive loss in old age[J]. Ann Neurol201883(1):74-83.
17
Schneider JA Arvanitakis Z Bang W,et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons[J]. Neurology200769(24):2197-2204.
18
Gatz M Reynolds CA Fratiglioni L,et al. Role of genes and environments for explaining Alzheimer disease[J]. Arch Gen Psychiatry200663(2):168-174.
19
Seath P Macedo-Orrego LE Velayudhan L. Clinical characteristics of early-onset versus late-onset Alzheimer’s disease:a systematic review and meta-analysis[J]. Int Psychogeriatr202436(12):1093-1109.
20
Polsinelli AJ Apostolova LG. Atypical Alzheimer disease variants[J]. Continuum(Minneap Minn)202228(3):676-701.
21
Armstrong RA. Risk factors for Alzheimer’s disease[J]. Folia Neuropathol201957(2):87-105.
22
Davidson Y Gibbons L Pritchard A,et al. Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer’s disease[J]. Dement Geriatr Cogn Disord200723(1):60-66.
23
Frisoni GB Pievani M Testa C,et al. The topography of grey matter involvement in early and late onset Alzheimer’s disease[J]. Brain2007130(Pt 3):720-730.
24
Kim EJ Cho SS Jeong Y,et al. Glucose metabolism in early onset versus late onset Alzheimer’s disease:an SPM analysis of 120 patients[J]. Brain2005128(Pt 8):1790-1801.
25
Shiino A Watanabe T Kitagawa T,et al. Different atrophic patterns in early- and late-onset Alzheimer’s disease and evaluation of clinical utility of a method of regional z-score analysis using voxel-based morphometry[J]. Dement Geriatr Cogn Disord200826(2):175-186.
26
Knopman DS Amieva H Petersen RC,et al. Alzheimer disease[J]. Nat Rev Dis Primers20217:33.
27
Isella V Licciardo D Nastasi G,et al. Clinical and metabolic imaging features of late-onset and early-onset posterior cortical atrophy[J]. Eur J Neurol202229(11):3147-3157.
28
Dubois B Feldman HH Jacova C,et al. Advancing research diagnostic criteria for Alzheimer’s disease:the IWG-2 criteria[J]. Lancet Neurol201413(6):614-629.
29
Jellinger KA. Pathobiological subtypes of Alzheimer disease[J]. Dement Geriatr Cogn Disord202049(4):321-333.
30
Kvello-Alme M Bråthen G White LR,et al. The prevalence and subtypes of young onset dementia in central Norway:a population-based study[J]. J Alzheimers Dis201969(2):479-487.
31
Qiu YQ Jacobs DM Messer K,et al. Cognitive heterogeneity in probable Alzheimer disease:clinical and neuropathologic features[J]. Neurology201993(8):e778-e790.
32
Crutch SJ Schott JM Rabinovici GD,et al. Consensus classification of posterior cortical atrophy[J]. Alzheimers Dement201713(8):870-884.
33
Rohrer JD. Structural brain imaging in frontotemporal dementia[J]. Biochim Biophys Acta20121822(3):325-332.
34
Montembeault M Brambati SM Gorno-Tempini ML,et al. Clinical,anatomical,and pathological features in the three variants of primary progressive aphasia:a review[J]. Front Neurol20189:692.
35
Henry ML Gorno-Tempini ML. The logopenic variant of primary progressive aphasia[J]. Curr Opin Neurol201023(6):633-637.
36
Ramanan S Irish M Patterson K,et al. Understanding the multidimensional cognitive deficits of logopenic variant primary progressive aphasia[J]. Brain2022145(9):2955-2966.
37
Sintini I Graff-Radford J Schwarz CG,et al. Longitudinal rates of atrophy and tau accumulation differ between the visual and language variants of atypical Alzheimer’s disease[J]. Alzheimers Dement202319(10):4396-4406.
38
Risacher SL Saykin AJ. Neuroimaging in aging and neurologic diseases[J]. Handb Clin Neurol2019167:191-227.
39
Holden SK Bettcher BM Pelak VS. Update on posterior cortical atrophy[J]. Curr Opin Neurol202033(1):68-73.
40
de Andrade KM Rodrigues CA Watanabe PC,et al. Styloid process elongation and calcification in subjects with tmd:clinical and radiographic aspects[J]. Braz Dent J201223(4):443-450.
41
Crutch SJ Lehmann M Schott JM,et al.Posterior cortical atrophy[J].Lancet Neurol201211(2):170-178.
42
Perry DC Brown JA Possin KL,et al. Clinicopathological correlations in behavioural variant frontotemporal dementia[J]. Brain2017140(12):3329-3345.
43
Bergeron D Sellami L Poulin S,et al. The behavioral/dysexecutive variant of Alzheimer’s disease:a case series with clinical,neuropsychological,and FDG-PET characterization[J]. Dement Geriatr Cogn Disord202049(5):518-525.
44
Dominguez Perez S Phillips JS Norise C,et al. Neuropsychological and neuroanatomical features of patients with behavioral/dysexecutive variant Alzheimer’s disease (AD):a comparison to behavioral variant frontotemporal dementia and amnestic AD groups[J]. J Alzheimers Dis202289(2):641-658.
45
Vigen CLP Mack WJ Keefe RSE,et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease:outcomes from CATIE-AD[J]. Am J Psychiatry2011168(8):831-839.
46
Sultzer DL Davis SM Tariot PN,et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease:phase 1 outcomes from the CATIE-AD effectiveness trial[J]. Am J Psychiatry2008165(7):844-854.
47
Townley RA Graff-Radford J Mantyh WG,et al. Progressive dysexecutive syndrome due to Alzheimer’s disease:a description of 55 cases and comparison to other phenotypes[J]. Brain Commun20202(1):fcaa068.
48
Corriveau-Lecavalier N Barnard LR Lee J,et al. Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease[J]. Cereb Cortex202333(11):7026-7043.
49
Smirnov DS Galasko D Hiniker A,et al. Age-at-onset and APOE-related heterogeneity in pathologically confirmed sporadic Alzheimer disease[J]. Neurology202196(18):2272-2283.
50
Mendez MF Moheb N Desarzant RE,et al. The progressive acalculia presentation of parietal variant Alzheimer’s disease[J]. J Alzheimers Dis201863(3):941-948.
51
Hassan A Whitwell JL Josephs KA. The corticobasal syndrome-Alzheimer’s disease conundrum[J]. Expert Rev Neurother201111(11):1569-1578.
52
Koga S Josephs KA Aiba I,et al. Neuropathology and emerging biomarkers in corticobasal syndrome[J]. J Neurol Neurosurg Psychiatry202293(9):919-929.
53
Alladi S Xuereb J Bak T, et al. Focal cortical presentations of Alzheimer’s disease[J]. Brain2007130(Pt 10):2636-2645.
54
Sha SJ Ghosh PM Lee SE,et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria,magnetic resonance imaging and fluorodeoxyglucose positron emission tomography[J]. Alzheimers Res Ther20157(1):8.
55
Graff-Radford J Yong KXX Apostolova LG,et al. New insights into atypical Alzheimer’s disease in the era of biomarkers[J]. Lancet Neurol202120(3):222-234.
56
Di Stefano F Kas A Habert MO,et al. The phenotypical core of Alzheimer’s disease-related and nonrelated variants of the corticobasal syndrome:a systematic clinical,neuropsychological,imaging,and biomarker study[J]. Alzheimers Dement201612(7):786-795.
57
Viswanathan A Greenberg SM. Cerebral amyloid angiopathy in the elderly[J]. Ann Neurol201170(6):871-880.
58
Koemans EA Chhatwal JP van Veluw SJ,et al. Progression of cerebral amyloid angiopathy:a pathophysiological framework[J]. Lancet Neurol202322(7):632-642.
59
Dörner M Tyndall A Hainc N,et al. Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy-a cross-sectional study[J]. Alzheimers Res Ther202416(1):196.
60
Planton M Raposo N Albucher JF,et al. Cerebral amyloid angiopathy-related cognitive impairment:The search for a specific neuropsychological pattern[J]. Rev Neurol(Paris)2017173(9):562-565.
61
Charidimou A Boulouis G Edip Gurol M,et al. Emerging concepts in sporadic cerebral amyloid angiopathy[J]. Brain2017140(7):1829-1850.
62
Corriveau-Lecavalier N Botha H Graff-Radford J,et al. Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome[J]. Brain Commun20246(4):fcae183.
63
Ferreira D Nordberg A Westman E. Biological subtypes of Alzheimer disease:a systematic review and meta-analysis[J]. Neurology202094(10):436-448.
64
Chen PD Yao HX Tijms BM,et al. Four distinct subtypes of Alzheimer’s disease based on resting-state connectivity biomarkers[J]. Biol Psychiatry202393(9):759-769.
65
Tijms BM Vromen EM Mjaavatten O,et al. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles[J]. Nat Aging20244(1):33-47.
66
Tijms BM Gobom J Reus L,et al. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics[J]. Brain2020143(12):3776-3792.
67
Neff RA Wang MH Vatansever S,et al. Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets[J]. Sci Adv20217(2):eabb5398.

基金

国家自然科学基金资助项目(82371444;72174159)

评论

PDF(549 KB)

Accesses

Citation

Detail

段落导航
相关文章

/